Caregiver Burden and Quality of Life Across Alzheimer's Disease Severity Stages

被引:4
作者
van Hezik-Wester, Valerie J. [1 ,2 ,6 ,7 ]
Handels, Ron L. H. [3 ,4 ,5 ]
Wolfs, Claire A. G. [3 ,4 ,5 ]
Kanters, Tim A. [1 ,2 ]
机构
[1] Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands
[2] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Rotterdam, Netherlands
[3] Maastricht Univ, Alzheimer Ctr Limburg, Med Ctr, Dept Psychiat & Neuropsychol, Maastricht, Netherlands
[4] Maastricht Univ, Fac Hlth Med & Life Sci, Maastricht, Netherlands
[5] Maastricht Univ, Sch Mental Hlth & Neurosci, Maastricht, Netherlands
[6] Erasmus Univ, Inst Med Technol Assessment, POB 1738, NL-3000 DR Rotterdam, Netherlands
[7] Erasmus Univ, Erasmus Sch Hlth Policy & Management, POB 1738, NL-3000 DR Rotterdam, Netherlands
关键词
alzheimer disease; dementia; caregiver burden; Informal care; health-related quality of life; INFORMAL CARE; HEALTH; INSTRUMENT; INCLUSION; QUESTIONNAIRE; RELIABILITY; VALIDITY; IMPACT;
D O I
10.1097/WAD.0000000000000558
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: The objective is to estimate the caregiver burden in terms of informal care time, health-related quality of life (HRQoL), and societal costs by disease severity (mild, moderate, or severe) and living situation (community-dwelling or institutionalized) of persons with AD (PwAD); and PwAD HRQoL. Methods: Caregivers were recruited through an online panel provider in the Netherlands. The survey used validated instruments, including iMTA Valuation of Informal Care Questionnaire, CarerQoL, and EQ-5D-5L. Results: One hundred two caregivers participated. PwADs received, on average, 26 hours of informal care per week. Informal care costs were higher for community-dwelling PwADs compared with institutionalized PwADs (euro480 and euro278, respectively). On the EQ-5D-5L, caregivers scored on average 0.797, reflecting a utility decrement of 0.065 compared with an age-matched population. Proxy-rated utility scores for PwADs decreased with increasing disease severity (0.455, 0.314, and 0.212 for mild, moderate, and severe AD, respectively). Institutionalised PwADs had lower utility scores than community-dwelling PwADs (0.590 vs. 0.421). There was no difference in informal care time, societal costs, CarerQol scores, and caregiver EQ-5D-5L scores between disease severities. Conclusion: The burden of AD extends to caregivers in terms of HRQoL and time investment, regardless of the disease severity of the target population. These impacts should be incorporated into the evaluation of new AD interventions.
引用
收藏
页码:134 / 141
页数:8
相关论文
共 34 条
[1]  
Andreakou Maria I, 2016, Int J Alzheimers Dis, V2016, P9213968, DOI 10.1155/2016/9213968
[2]  
[Anonymous], RFID in de Gezondheidszorg-experiment met RFID in de Zorg: eindrapportage van een drietal pilots in het AMC
[3]   Prevalence of Mental Health Disorders Among Caregivers of Patients With Alzheimer Disease [J].
Bin Sallim, Adnaan ;
Sayampanathan, Andrew Arjun ;
Cuttilan, Amit ;
Ho, Roger Chun-Man .
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2015, 16 (12) :1034-1041
[4]   Changes in caregiver burden and health-related quality of life of informal caregivers of older people with Dementia: evidence from the European RightTimePlaceCare prospective cohort study [J].
Bleijlevens, Michel H. C. ;
Stolt, Minna ;
Stephan, Astrid ;
Zabalegui, Adelaida ;
Saks, Kai ;
Sutcliffe, Caroline ;
Lethin, Connie ;
Soto, Maria E. ;
Zwakhalen, Sandra M. G. .
JOURNAL OF ADVANCED NURSING, 2015, 71 (06) :1378-1391
[5]   The iMTA Productivity Cost Questionnaire A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses [J].
Bouwmans, Clazien ;
Krol, Marieke ;
Severens, Hans ;
Koopmanschap, Marc ;
Brouwer, Werner ;
Hakkaart-van Roijen, Leona .
VALUE IN HEALTH, 2015, 18 (06) :753-758
[6]   Process utility from providing informal care: the benefit of caring [J].
Brouwer, WBF ;
van Exel, NJA ;
van den Berg, B ;
van den Bos, GAM ;
Koopmanschap, MA .
HEALTH POLICY, 2005, 74 (01) :85-99
[7]   The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra [J].
Brouwer, Werner B. F. .
PHARMACOECONOMICS, 2019, 37 (04) :451-456
[8]  
Centraal Bureau voor de Statistiek, VAC SBI 2008 NAAR EC
[9]   Alzheimer's disease drug development pipeline: 2020 [J].
Cummings, Jeffrey ;
Lee, Garam ;
Ritter, Aaron ;
Sabbagh, Marwan ;
Zhong, Kate .
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2020, 6 (01)
[10]   The Inclusion of Informal Care in Applied Economic Evaluation: A Review [J].
Goodrich, Kacey ;
Kaambwa, Billingsley ;
Al-Janabi, Hareth .
VALUE IN HEALTH, 2012, 15 (06) :975-981